论文部分内容阅读
目前涉及受体酪氨酸激酶(RTKs)的染色体重排已在上皮恶性肿瘤中描述,包括非小细胞肺癌、结直肠癌和乳腺癌。一种受体酪氨酸激酶c-ros原癌基因1受体酪氨酸激酶已经被确认为非小细胞肺癌的驱动基因,因为其能被克唑替尼(一种间变性淋巴瘤受体酪氨酸激酶ALK/肝细胞生长因子受体c-Met/ROS1抑制剂)作用后可使肿瘤明显缩小。最近研究表明对进展期胃癌,目前只有人表皮生长因子受体2(HER-2)基因阳性的患者可以通过化疗联合靶向治疗延长其生存期。但进展期胃癌患者中,HER-2阳性率不足1/4,我国患者的比例可能更低。因此,有必要进一步探索胃癌新
Current chromosomal rearrangements involving receptor tyrosine kinases (RTKs) have been described in epithelial malignancies including non-small cell lung cancer, colorectal cancer and breast cancer. A receptor tyrosine kinase c-roson oncogene 1 receptor tyrosine kinase has been identified as a driver of non-small cell lung cancer because of its ability to be metabolized by crizotinib (an anaplastic lymphoma receptor Tyrosine kinase ALK / hepatocyte growth factor receptor c-Met / ROS1 inhibitor) can make the tumor significantly reduced. Recent studies have shown that in patients with advanced gastric cancer, only the positive human epidermal growth factor receptor 2 (HER-2) gene-positive patients by chemotherapy combined with targeted therapy to extend its survival. However, patients with advanced gastric cancer, HER-2-positive rate of less than 1/4, the proportion of patients in our country may be lower. Therefore, it is necessary to further explore new gastric cancer